Improving the quality of care.
Daiichi Sankyo, Inc. believes that Managed Care Organizations, health plans, medical groups, pharmacists, and hospital systems all play a vital role in maintaining a high-quality healthcare system. That’s why we are dedicated to building relationships with customers that help enhance the quality of healthcare for patients. We achieve this goal by utilizing research, science, and treatment modalities to empower patients and help healthcare providers improve quality of care. By focusing on creative patient-centric solutions, we develop new ways of delivering high quality services to our healthcare customers.
Daiichi Sankyo has a solid record of success in our core categories of anti-hypertensives, hyperlipidemia, type 2 diabetes, and anti-platelet therapies and we are excited to be moving into fields such as oncology and anti-coagulants.
We pursue alliances with other pharmaceutical and biotech companies that complement our in-house portfolio and capabilities. Most recently, Daiichi Sankyo accelerated our position in oncology and strengthened our pipeline with the acquisition of Plexxikon, Inc.
It is important to us that appropriate patients who need our medicines have access to our therapies and to our population health management programs. We work closely with Managed Care Organizations, medical groups, hospital systems, employer coalitions, and pharmacies to help achieve this objective.
Alliances committed to quality healthcare